Adiponectin inhibits the binding of low-density lipoprotein to biglycan, a vascular proteoglycan.
The aim of this study was to test the possibility that adiponectin has an antiatherogenic effect through the inhibition of LDL binding to proteoglycans, an initial event in atherogenesis. Both full-length and globular adiponectin inhibited LDL binding in a dose-dependent manner. Both types of adiponectin bound to biglycan in a dose-dependent manner. Immunoprecipitation and immunoblotting analysis showed interaction of full-length adiponectin with LDL. Pretreatment of biglycan with globular adiponectin prior to LDL addition diminished the inhibitory effect, while pretreatment with full-length adiponectin retained the effect. This is a new antiatherogenic property that appears independent of the receptor-mediated hormonal action of adiponectin.
Kobayashi
Kunihisa
K
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan. nihisak@intmed3.med.kyushu-u.ac.jp
Inoguchi
Toyoshi
T
Sonoda
Noriyuki
N
Sekiguchi
Naotaka
N
Nawata
Hajime
H
D052242:Adiponectin; D058578:Biglycan; D004305:Dose-Response Relationship, Drug; D024202:Electrophoretic Mobility Shift Assay; D016326:Extracellular Matrix Proteins; D047468:Immunoprecipitation; D036341:Intercellular Signaling Peptides and Proteins / Q000494:pharmacology*; D008077:Lipoproteins, LDL / Q000378:metabolism*; D011485:Protein Binding / Q000187:drug effects; D011509:Proteoglycans / Q000378:metabolism*
D052242:Adiponectin; D058578:Biglycan; D016326:Extracellular Matrix Proteins; D036341:Intercellular Signaling Peptides and Proteins; D008077:Lipoproteins, LDL; D011509:Proteoglycans